HALOPERIDOL AND ATTENTIONAL LEARNING IN AUTISTISM

芬氟拉明治疗婴儿自闭症的疗效最近得到了 大量的宣传。 这似乎是一种很有希望的治疗方法， 人口 然而，精心设计的研究和仔细的监测， 为了确定这种药物的作用，需要住院治疗。 我们希望严格评估短期和长期的有效性和安全性 芬氟拉明及其对自闭症儿童学习的影响， 将其与氟哌啶醇和安慰剂进行比较。 选择氟哌啶醇作为 因为它对行为症状和学习的影响 和它的安全性在我们单位进行了一段时间的系统研究： 我们已经证明了它在统计学和临床上都具有上级优势 在设计良好的研究中， 在双盲条件下。 我们选择的设计是这样的， 每一个孩子都将作为自己的对照。 儿童（N=42;年龄2至7岁 将使用DSM-III标准仔细诊断婴儿 自闭症，完全综合征存在;已知自闭症病因的患者（Axis 三）将不包括在实验中，从而增加了 样品的均匀性。 短期研究将持续一段时间， 14周和3年以上的长期研究。 无论是短期还是长期 研究，任务，措施，战略和规模将用于我们的 氟哌啶醇之前的研究 我们有专业知识和经验 进行这种类型的研究，人口和所需的 包括自动化实验室在内的设施。 我们还显示， 过去，我们能够实现100%的药物依从性， 按时完成研究的能力。 比较2种药物 不同的行动，如芬氟拉明和氟哌啶醇，可以帮助我们， 每个人都有自己的故事，每个人都有自己的故事，都有自己的故事。 异质性综合征 该项目也是对以下研究的重大贡献： 药物引起的运动障碍 这是唯一的前瞻性研究项目 这些不正常的不自主运动在一个人群中， 与长期药物无关的基线异常运动率 局

The efficacy of fenfluramine in infantile autism has received recently a great deal of publicity. It appears to be a promising treatment in this population. However, well designed research and careful monitoring in an inpatient setting is required in order to determine the role of this drug. We wish to assess critically the short- and long-term efficacy and safety of fenfluramine and its effects on learning in autistic children, and to compare them to those of haloperidol and placebo. Haloperidol is chosen as a control drug, because its effects on behavioral symptoms and on learning and its safety were systematically investigated for some time in our unit: we have demonstrated that it is both statistically and clinically superior to placebo in autistic children when administered in well designed studies under double-blind conditions. The design we have chosen is such, that each child will serve as his own control. The children (N=42; ages 2 to 7 years) will be carefully diagnosed using DSM-III criteria for Infantile Autism, Full Syndrome Present; those with known causes for autism (Axis III) will not be included in the experiment, thus increasing the homogeneity of the sample. The short-term study will be over a period of 14 weeks and the long-term study over 3 years. In both short and long-term studies, tasks, measures, strategies and scales will be used as in our previous research with haloperidol. We have the expertise and experience to conduct this type of research, the population and the required facilities which include an automated laboratory. We also have shown in the past that we are able to achieve 100% drug compliance and have the ability to complete a study on time, as scheduled. Comparing 2 drugs of different actions, such as fenfluramine and haloperidol, may aid us in delineating responders to each and, thus, to shed some light on this heterogenous syndrome. This project also represents a major contribution to research in drug-induced dyskinesias. It is the only prospective project to study these abnormal involuntary movements in a population which has a high baseline rate of abnormal movements unrelated to long-term drug administration.